AbbVie clinches back-to-back clinical wins in ulcerative colitis, lupus

In a double data drop Thursday, AbbVie touted two clinical trial wins. Topline data from the Phase III INSPIRE study showed Skyrizi (risankizumab) met its primary and all secondary endpoints in ulcerative colitis (UC).